Table 1.
In vitro antileishmanial activity of thiadiazole derivatives 1a-b and 5a-b against promastigote form of Leishmania major
 | |||||
|---|---|---|---|---|---|
| Compounds | R | X | Anti-promastigote activity IC50 (μM) | Cytotoxicity CC50 (μM)a | SIb |
| 1a |  |
O | 18 ± 0.2 | 62.33 | 3.46 |
| 1b |  |
S | 3 ± 0.41 | 42.16 | 14.05 |
| 5a |  |
O | 68.9 ± 0.107 | 78.54 | 1.14 |
| 5b |  |
S | 27 ± 0.12 | 63.55 | 2.35 |
| Glucantime | - | - | 68.44c | - | - |
| Fluconazole | - | - | 941.1 ± 4.98 | - | - |
a
Cytotoxicity was evaluated against mouse peritoneal macrophages.
b
Selectivity index (SI) CC50/IC50.
c
The IC50 of Glucantime was in mM.